全文获取类型
收费全文 | 358篇 |
免费 | 20篇 |
国内免费 | 12篇 |
专业分类
耳鼻咽喉 | 2篇 |
儿科学 | 40篇 |
妇产科学 | 3篇 |
基础医学 | 19篇 |
口腔科学 | 10篇 |
临床医学 | 38篇 |
内科学 | 80篇 |
皮肤病学 | 5篇 |
神经病学 | 9篇 |
特种医学 | 70篇 |
外科学 | 27篇 |
综合类 | 16篇 |
预防医学 | 13篇 |
药学 | 36篇 |
肿瘤学 | 22篇 |
出版年
2023年 | 1篇 |
2022年 | 1篇 |
2020年 | 3篇 |
2019年 | 5篇 |
2018年 | 8篇 |
2017年 | 9篇 |
2016年 | 2篇 |
2015年 | 6篇 |
2014年 | 10篇 |
2013年 | 16篇 |
2012年 | 14篇 |
2011年 | 9篇 |
2010年 | 22篇 |
2009年 | 16篇 |
2008年 | 6篇 |
2007年 | 10篇 |
2006年 | 12篇 |
2005年 | 8篇 |
2004年 | 5篇 |
2003年 | 12篇 |
2002年 | 2篇 |
2001年 | 5篇 |
2000年 | 7篇 |
1999年 | 14篇 |
1998年 | 29篇 |
1997年 | 19篇 |
1996年 | 21篇 |
1995年 | 17篇 |
1994年 | 16篇 |
1993年 | 13篇 |
1992年 | 5篇 |
1991年 | 2篇 |
1990年 | 6篇 |
1989年 | 8篇 |
1988年 | 5篇 |
1987年 | 7篇 |
1986年 | 8篇 |
1985年 | 5篇 |
1984年 | 4篇 |
1983年 | 4篇 |
1982年 | 3篇 |
1981年 | 4篇 |
1980年 | 1篇 |
1979年 | 3篇 |
1977年 | 3篇 |
1976年 | 2篇 |
1975年 | 1篇 |
1950年 | 1篇 |
排序方式: 共有390条查询结果,搜索用时 15 毫秒
41.
42.
43.
44.
Study Type – Harm (Cohort) Level of Evidence 2b What’s known on the subject? and What does the study add? In clinical trials, oral medications for BPH have been effective at managing LUTS and preventing progression to urinary retention, urinary infections, and renal insufficiency. Population‐level trends of these adverse outcomes are poorly characterized. We identified a 400% increase in hospitalizations for BPH with acute renal failure, indicating that severe adverse events of BPH persist despite widespread use of oral therapies in the USA.
OBJECTIVE
? To determine if the adverse events (AEs) of benign prostatic hyperplasia (BPH) have declined in tandem with increased use of oral therapy.MATERIALS AND METHODS
? We used the Nationwide Inpatient Sample, a 20% sample of USA community hospitals, weighted to estimate national numbers to characterize the prevalence of AEs of BPH from 1998 to 2008. ? We calculated the age‐adjusted prevalence of BPH and associated conditions and analyzed prevalence trends with regression modelling.RESULTS
? Of 134 million estimated eligible discharges during the study period, 7 464 730 (5.6%) had either a primary or secondary diagnosis of BPH. ? The age‐adjusted prevalence of BPH among all hospitalizations, irrespective of primary diagnosis, increased from 4.3% to 8% (P < 0.001) during the study period. ? The age‐adjusted prevalence of BPH as a primary diagnosis decreased from 0.88% to 0.48% (P < 0.001). ? Discharges for BPH surgery decreased 51% (odds ratio [OR] 0.49, 95% confidence interval [CI] 0.45–0.54, P‐trend <0.001) over time. Discharges for primary BPH with acute renal failure increased >400% (OR 4.28, 95% CI 3.22–5.71, P‐trend <0.001). ? There were no significant changes in discharges for primary BPH with urinary retention (P‐trend = 0.636), bladder stones (P‐trend = 0.117), or urinary infection (P‐trend = 0.101) over time.CONCLUSIONS
? Increased hospitalizations for BPH with acute renal failure and stable hospitalizations for other AEs of BPH indicate that severe AEs of BPH persist despite widespread use of oral therapies in the USA. ? Further studies are needed to explain these trends. 相似文献45.
Francis KL CHAN 《Journal of digestive diseases》2005,6(1):1-5
Whether Helicobacter pylori infection alters the risk of ulcer disease in patients receiving nonsteroidal anti‐inflammatory drugs (NSAIDs) or low‐dose aspirin is one of the most controversial topics in peptic ulcer research. This is an important management issue, particularly in countries where peptic ulcer disease is common and the prevalence of H. pylori infection is high. Current evidence shows that H. pylori infection increases the ulcer risk associated with NSAIDs or low‐dose aspirin. Eradication of H. pylori reduces the subsequent risk of endoscopic and complicated ulcers in patients who are about to start long‐term NSAIDs. Among patients with H. pylori infection and a history of ulcer bleeding who continue to use low‐dose aspirin, 1 week of eradication therapy prevents recurrent ulcer bleeding. Failure of eradication and concomitant use of NSAIDs, however, account for most cases of recurrent bleeding with low‐dose aspirin. The apparent protective effect of H. pylori in long‐term NSAIDs users reported in some studies was actually the weeding out of susceptible patients who were intolerant to NSAIDs. There is no convincing evidence that eradication of H. pylori has any clinically important adverse effect on the healing and prevention of ulcers in NSAIDs users. 相似文献
46.
世界胃肠病学组织(WGO-OMGE)临床指南——发展中国家幽门螺杆菌感染 总被引:16,自引:1,他引:16
Hunt RH Xiao SD Megraud F Leon-Barua R Bazzoli F Van der Merwe S vaz Coelho LG Fock KM Fedail S Cohen H Malfertheiner P Vakil N Hamid S Goh KL Wong BC Krabshuis JH 杜颖 丛衍群 戴宁 《胃肠病学》2007,12(1):40-52
我非常高兴向大家推荐这份发展中国家幽门螺杆菌(H.priori)临床指南。该指南的编译是由数位在该领域具有丰富临床经验的世界知名专家共同完成的。 相似文献
47.
Background
Pneumocystis jiroveci pneumonia (PCP) is an important opportunistic infection among immunosuppressed patients, especially in those infected with human immunodeficiency virus (HIV). The clinical presentation of PCP in immunosuppressed patients have been well-reported in the literature. However, the clinical importance of PCP manifesting in the setting of an immunorestitution disease (IRD), defined as an acute symptomatic or paradoxical deterioration of a (presumably) preexisting infection, which is temporally related to the recovery of the immune system and is due to immunopathological damage associated with the reversal of immunosuppressive processes, has received relatively little attention until recently. 相似文献48.
Priming of human neutrophils with N-formyl-methionyl-leucyl- phenylalanine by a calcium-independent, pertussis toxin-insensitive pathway 总被引:1,自引:0,他引:1
Resting neutrophils may be "primed" to augmented effector function, eg, superoxide (O2-) production in the respiratory burst, upon a second stimulation with a variety of soluble agonists including formylated methionyl-leucyl-phenylalanine (FMLP) and phorbol myristate acetate (PMA). At priming concentrations of FMLP (5 x 10(-9) mol/L) that did not initiate O2- generation, two metabolic activities were noted: (1) approximately a threefold increase in the baseline intracellular calcium (Ca++i) level, that was not dependent on extracellular Ca++, and (2) a rapid rise in intracellular pH that was blocked by 5-(N,N- dimethyl) amiloride (DA), that had no effect on the Ca++i response to priming. Furthermore, there were no significant increases in inositol metabolites in cells primed and stimulated with FMLP compared with cells receiving the stimulating dose of FMLP alone and pretreatment with pertussis toxin (PT) (before the addition of the priming -5 x 10(- 9) mol/L dose of FMLP), whereas abolishing the response to FMLP during the second stage of stimulation, had (1) no effect on FMLP-primed cells subsequently stimulated with PMA, and (2) only partially ablated the rise in Ca++i initiated with FMLP. That FMLP priming involved distinctive processes to those of the well characterized FMLP-coupled Ca++-dependent activation cascade was shown by the full priming effect attained in a Ca++-free buffer, which did not sustain an O2- response to a second-stage FMLP stimulation, but sustained a primed response to PMA. These data demonstrate that FMLP primes human neutrophils by a Ca++-independent and PT-insensitive pathway, offering a functional model for studying heterogeneous FMLP receptor-coupled reactions. 相似文献
49.
50.
NICHOLAS J TALLEY SK LAM KL GOH KM FOCK 《Journal of gastroenterology and hepatology》1998,13(4):335-353
Dyspepsia is most optimally defined as pain or discomfort centred in the upper abdomen. The symptom complex may be caused by peptic ulcer disease, gastro-oesophageal reflux, or gastric cancer but is most often due to functional (or non-ulcer) dyspepsia. While upper endoscopy is the method of choice to determine the underlying cause of dyspepsia, it is expensive. A more pragmatic approach is needed in the Asia-Pacific region where health services are limited. A detailed treatment algorithm is given for managing patients presenting with new-onset dyspepsia and documented functional dyspepsia after endoscopy, and evidence to support this approach is reviewed. Prompt endoscopy is recommended for patients with alarm features. In patients without alarm features, treatment for 2–4 weeks with an empirical anti-secretory or prokinetic agent, followed by investigation using non-invasive Helicobacter pylori testing and treatment for patients who do not respond or relapse, is recommended. Trials of management strategies are now needed to establish the efficacy and cost-effectiveness of the approaches recommended. 相似文献